Discover 1,107 paid clinical trials in Alabama. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Alabama provides a diverse range of research opportunities for healthy volunteers and individuals with specific health conditions. Leading research centers in Birmingham, Montgomery, and Mobile are seeking participants, offering access to innovative treatments and cutting-edge medical care.
Filter
1
Filter results
Results: 1,107
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
for
Chronic Kidney Disease(CKD), Type 2 DM,
Location: Durham NC, Houston NC, St. Petersburg FL, Ann Arbor MI,
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06906627
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
for
Heart Failure - NYHA II - IV
Location: Fall River MA, Flushing NY, New York NY, Albany NY,
Sponsor: Boston Scientific Corporation
Sex: All
Age: 18+
Code: NCT07069738
Recruiting
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
for
Chronic Kidney Disease(CKD), Type 2 DM,
Location: Durham NC, St. Petersburg FL, Ann Arbor MI,
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06906640
Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Boston MA, Valhalla NY, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 21
Code: NCT04870944
Phase1, Phase2, Recruiting
I-DECIDE After Bronchiolitis Hospitalization
for
Bronchiolitis Acute
Location: Bangor ME, Boston MA, Providence RI, Manchester NH,
Sponsor: Seattle Children's Hospital
Sex: All
Age: 0 - 2
Code: NCT07243652
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement